| Market Cap | 22.39M | P/E | - | EPS this Y | 65.40% | Ern Qtrly Grth | - |
| Income | -12.2M | Forward P/E | -1.43 | EPS next Y | -64.90% | 50D Avg Chg | -38.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -48.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -71.00% |
| Recommedations | 1.50 | Quick Ratio | 0.35 | Shares Outstanding | 29.89M | 52W Low Chg | 9.00% |
| Insider Own | 39.10% | ROA | -480.74% | Shares Float | 17.22M | Beta | 0.62 |
| Inst Own | 30.81% | ROE | - | Shares Shorted/Prior | 145.37K/112.45K | Price | 2.61 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 258,846 | Target Price | 8.75 |
| Oper. Margin | - | Earnings Date | Nov 12 | Volume | 23,507 | Change | -10.00% |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Farfel Gail M | Chief Executive Offi.. Chief Executive Officer | Dec 14 | Buy | 4.94 | 1,000 | 4,940 | 2,000 | 12/16/22 |
| Kirwin Patrick D. | Director Director | Dec 13 | Buy | 4.69 | 3,000 | 14,070 | 27,998 | 12/15/22 |
| Williams Eugene | Director Director | Dec 07 | Buy | 5.4864 | 1,000 | 5,486 | 156,930 | 12/08/22 |
| Farfel Gail M | Chief Executive Offi.. Chief Executive Officer | Dec 06 | Buy | 5.7 | 1,000 | 5,700 | 1,000 | 12/08/22 |
| Williams Eugene | Director Director | Dec 02 | Buy | 5.98 | 1,000 | 5,980 | 155,930 | 12/06/22 |
| Williams Eugene | Chairman and CEO Chairman and CEO | Jul 11 | Buy | 9.80 | 1,000 | 9,800 | 154,930 | 07/12/22 |